Freshly developed antibodies, ready for the next step.
Today marks an important milestone for Padakonn Pharma: the company’s monoclonal antibodies are now entering validation in a clinically relevant human setting. The Technology Readiness Level 5 (TRL5) study has officially started at the University of Tartu and Tartu University Hospital.
As part of the study, Padakonn Pharma’s monoclonal antibodies targeting marinobufagenin (MBG) will be tested using blood samples from patients with chronic kidney disease (CKD). The work will focus on the antibodies’ ability to restore Na+/K+-ATPase (NKA) function and reverse MBG-driven pathological signaling.
Using patient-derived blood samples allows the research team to evaluate the anti-MBG antibodies in a setting that more closely reflects human CKD biology. This is a validation study using patient samples; the antibodies are not being administered to patients as part of this work.
The TRL5 study is an important step in evaluating the therapeutic potential of Padakonn Pharma’s approach and defining the evidence needed for the next stage of drug development. It moves the programme closer to real-world clinical relevance while maintaining a clear focus on chronic kidney disease, NKA function, and MBG-driven signaling.
Padakonn Pharma is grateful to its collaborators at the University of Tartu and Tartu University Hospital for helping the company reach this stage and for supporting the validation of its monoclonal antibody platform in a clinically relevant human setting.
Another important step forward for Padakonn Pharma.
